Skip to main content
Homepage
PARTIAL Analysis Report
Sep 4, 2026
58 days ago · 2% complete
Partial analysis — no complete end-to-end run on record.
No report run on this ticker yet Only preliminary foundational data below
NOT YET RESEARCHED No report has been run on HROW yet. What you are seeing is foundational data only — price, profile and filings — not the full analysis (lenses, memo, scores and the AI panel arrive with the first report).
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Harrow Inc. (HROW) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at voiceoftrades.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Harrow Inc.

HROW NASDAQ
Healthcare · Drug Manufacturers - Specialty & Generic
Nashville, TN 37215, United States harrow.com Updated Nov 1, 10:20pm
Price
$33.08
Market Cap
$1.2B
Employees
373
Beta
0.24
Avg Volume
562,257
CEO
Mr. Mark L. Baum J.D.
GICS Category PDF

Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S. market. Its portfolio includes prescription and non-prescription therapies used by eye care professionals to manage conditions affecting the front and back of the eye, such as dry eye disease, glaucoma, cataracts, retinal disorders, allergies, and infections. Harrow operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business, giving it a broad commercial footprint across eye care settings. The company’s products are used in physician offices, clinics, and surgical environments, supporting routine treatment as well as specialized ophthalmic care. Headquartered in Nashville, Tennessee, Harrow focuses on accessible eye care solutions and a product mix that spans branded, compounded, and other ophthalmic formulations.

Runs with full report
Price Overview
Current data · timestamped when a report runs
$33.08
Change
-0.05 (-0.15%)
Day Range
$31.90 – $33.34
52-Week Range
$28.54 – $54.85
50-Day MA
$39.32
200-Day MA
$41.07
Volume
1,742,400.00
Share Structure
Outstanding 37,484,233.00
Float 28,929,749.00
Free Float 77.2%
Normal free float — 77.2% of shares trade freely, ~22.8% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Nov 1, 2026 10:20pm (just now)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics TTM · through Jun 30, 2026
TD Twelve Data statement HEX SEC filing
P/E · trailing (TTM) (Price per dollar of earnings over the past year — not a run-rate or forward P/E)
HEX
Stock Price / EPS (Diluted)
-33.61
Stock Price: $33.08
EPS (Diluted): -0.98
P/B Ratio (Price vs net asset value)
HEX
Stock Price / Book Value Per Share
84.27
Stock Price: $33.08
Total Equity: $14.85M
Shares: 37,818,909
EV/EBITDA (Total value vs operating profit)
HEX
Enterprise Value / EBITDA
-1,308.71
Market Cap: $1.24B
Total Debt: $0.00
Cash: $83.89M
EBITDA: -$880,000
Enterprise Value (Takeover price (cap + debt - cash))
HEX
Market Cap + Total Debt - Cash
$1.2B
Market Cap: $1.24B
Total Debt: $0.00
Cash: $83.89M
P/S Ratio (Price per dollar of revenue)
HEX
Stock Price / Revenue Per Share
4.54
Stock Price: $33.08
Revenue: $275.59M
Shares: 37,818,909
EV/Sales (Total value vs revenue — works when P/E can't)
CALC
4.18
Gross Margin (Revenue left after direct costs)
HEX
Gross Profit / Revenue
73.3%
Gross Profit: $201.96M
Revenue: $275.59M
Operating Margin (Revenue left after all operations)
HEX
Operating Income / Revenue
-1.0%
Operating Income: -$2.75M
Revenue: $275.59M
Net Margin (Revenue left as actual profit)
HEX
Net Income / Revenue
-13.5%
Net Income: -$37.23M
Revenue: $275.59M
ROE (Profit from shareholder equity)
HEX
Net Income / Total Equity
-116.1%
Net Income: -$37.23M
Total Equity: $14.85M
ROIC (Profit from all invested capital)
HEX
NOPAT / Invested Capital
4.0%
Operating Income: -$2.75M
Tax Rate: -0.1%
Equity: $14.85M
Total Debt: $0.00
Cash: $83.89M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
HEX
Current Assets / Current Liabilities
2.24
Current Assets: $229.31M
Current Liabilities: $102.17M
Debt/Equity (Leverage — debt vs equity)
HEX
Total Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $14.85M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
HEX
Revenue / Shares Outstanding
$7.29
Revenue: $275.59M
Shares: 37,818,909
Book Value/Share (Net assets per share)
HEX
(Total Assets - Total Liabilities) / Shares
$0.39
Total Equity: $14.85M
Shares: 37,818,909
FCF/Share (Real cash generated per share)
HEX
(Operating Cash Flow + CapEx) / Shares
$0.13
Operating CF: $6.25M
CapEx: -$1.24M
Shares: 37,818,909
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TD
Last Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $33.08
Payout Ratio (Earnings paid out as dividends)
HEX
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$37.23M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Nov 1, 2026 10:20pm (just now)
Metric 2021 2022 2023 2024 2025
Revenue $72.5M $88.6M $130.2M $199.6M $272.3M
Cost of Revenue $18.2M $25.4M $39.6M $49.2M $67.9M
Gross Profit $54.3M $63.2M $90.6M $150.4M $204.4M
Operating Expenses $52.6M $61.3M $90.1M $141.5M $173.9M
Operating Income $1.6M $1.9M $431,000 $8.8M $30.5M
Net Income -$18.0M -$14.1M -$24.4M -$17.5M -$5.1M
EBITDA $3.3M $3.4M $2.0M $10.7M $32.4M
EPS $-0.48 $-0.38 $-0.75 $-0.49 $-0.14
EPS (Diluted) — $-0.38 $-0.75 $-0.49 $-0.14
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $42.2M $96.3M $74.1M $47.2M $72.9M
Total Current Assets $60.7M $118.3M $139.5M $189.7M $211.8M
Total Assets $98.3M $157.4M $312.2M $389.0M $399.5M
Current Liabilities $9.7M $18.6M $49.3M $91.3M $96.3M
Long-Term Debt $103.0M $151.8M $246.7M $262.7M $250.0M
Total Liabilities $87.4M $130.1M $241.8M $319.7M $347.4M
Total Equity $10.9M $27.2M $70.4M $69.3M $52.1M
Retained Earnings -$95.4M -$109.5M -$133.9M -$151.4M -$156.5M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $5.1M $1.7M $3.8M -$22.2M $43.9M
Capital Expenditure -$1.8M -$2.6M -$1.5M -$1.6M $-887,000
Free Cash Flow $3.3M $-892,000 $2.4M -$23.8M $43.0M
Acquisitions (net) — — — — —
Net Debt Issued / (Repaid) — — $55.9M $29.8M $244.4M
Dividends Paid — — — — —
Stock Buybacks — — — — —
Net Change in Cash $37.9M $54.1M -$22.2M -$26.8M $25.7M
Growth Trends (YoY %)
Last updated: Nov 1, 2026 10:20pm (just now)
Metric 2022 2023 2024 2025
Revenue Growth +22.2% +47.0% +53.3% +36.4%
Gross Profit Growth +16.5% +43.3% +66.1% +35.9%
Operating Income Growth +18.9% -77.5% +1,946.9% +245.9%
Net Income Growth +21.8% -73.3% +28.4% +70.6%
EBITDA Growth +2.0% -42.3% +444.2% +203.9%
Industry Benchmarks
Compares HROW against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable not yet run 1 computed · 6 not applicable · 17 not yet run
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for HROW — it's generated by the pipeline (market-narrative step).
Claude Reading
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
No AI findings yet for HROW — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Reading
GPT reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No GPT reading yet for HROW — it's generated by the pipeline (gpt-critique step) after the other Big-3 seats, when a report is run on this ticker.
Grok Reading
Grok (xAI) reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No Grok reading yet for HROW — it's generated by the pipeline (grok-critique step) alongside the other Big-3 seats, when a report is run on this ticker.
Advanced Analysis Forensic deep-dive · separate lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Community AI Feedback
No community reviews yet for HROW. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this